Drug Shortage Report for HALOPERIDOL INJECTION, USP
Report ID | 50916 |
Drug Identification Number | 02406411 |
Brand name | HALOPERIDOL INJECTION, USP |
Common or Proper name | HALOPERIDOL |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | HALOPERIDOL |
Strength(s) | 5MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAMUSCULAR |
Packaging size | 1mL MD Vial |
ATC code | N05AD |
ATC description | ANTIPSYCHOTICS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2018-05-28 |
Actual start date | |
Estimated end date | |
Actual end date | 2018-08-02 |
Shortage status | Resolved |
Updated date | 2018-08-10 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v5 | 2018-08-10 | French | Compare |
v4 | 2018-08-10 | English | Compare |
v3 | 2018-05-30 | French | Compare |
v2 | 2018-05-30 | English | Compare |
v1 | 2018-05-30 | English | Compare |
Showing 1 to 5 of 5